DW-0929

Daewon Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

DW-0929 is an investigational therapeutic agent in phase 3 development by Daewon Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.

At a glance

Generic name	DW-0929
Sponsor	Daewon Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism remain unknown. Phase 3 status indicates the drug has demonstrated sufficient safety and efficacy in earlier trials to warrant large-scale clinical testing, but mechanistic details are typically proprietary until publication or regulatory approval.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DW-0929 CI brief — competitive landscape report
DW-0929 updates RSS · CI watch RSS
Daewon Pharmaceutical Co., Ltd. portfolio CI